Keisuke Shirai, MD
Hematology & Oncology · Lebanon, NHNPI 1992892905
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,940 of the $5,087 with a category attached, or 97.1%. 4 manufacturers reported payments, led by Chugai Pharmaceutical Co., Ltd. at 59.8% of the total. Reporting peaked in 2021 at $1,900 and has fallen 93.9% since, to $116 in 2025. Among hematology & oncology clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $847.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chugai Pharmaceutical Co., Ltd.$3K
- Eisai CO., LTD.$2K
- Regeneron$116
- Merck$31
Across 146 payments — averaging $6249.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$211K
- Daiichi Sankyo Inc.$147K
- AbbVie$139K
- E.r. Squibb & Sons, L.L.C.$77K
- Astellas Pharma Global Development$47K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- plus $242K from 7 others
What the payments were for
- Consulting fees$4,94097%
- Food & beverage$1162%
- Education$311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | 2 | $3,040 |
| Eisai CO., LTD. | 1 | $1,900 |
| Regeneron | 1 | $116 |
| Merck | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,087 in reported general payments places this provider in the 90th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 35 | $558,269 |
| EliquisApixaban | 55 | $23,104 |
| Prednisone | 251 | $1,333 |
| Morphine Sulfate ErMorphine Sulfate | 51 | $988 |
| Propranolol Hcl ErPropranolol Hcl | 22 | $973 |
| Levothyroxine Sodium | 108 | $897 |
| Ondansetron Hcl | 25 | $768 |
| Hydrocortisone | 22 | $615 |
| Potassium Chloride | 27 | $544 |
| Prochlorperazine Maleate | 36 | $390 |
| Gabapentin | 33 | $360 |
| Oxycodone Hcl | 30 | $324 |
| Dexamethasone | 15 | $321 |
| Morphine Sulfate | 13 | $243 |
| Duloxetine Hcl | 27 | $208 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lebanon
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Konstantin DragnevLebanon$5K
- Ivy Riano MonsalveLebanon$2K
- Kenneth MeehanLebanon$711
- John HillLebanon$687
- Young Soo RhoLebanon$475
- Gabriella HarmonLebanon$273
- Sergey DevitskiyLebanon$192
- Elizabeth BengtsonLebanon$120
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.